148 results on '"Jae Myung Yu"'
Search Results
2. Pioglitazone as Add-on Therapy in Patients with Type 2 Diabetes Mellitus Inadequately Controlled with Dapagliflozin and Metformin: Double-Blind, Randomized, Placebo-Controlled Trial
- Author
-
Ji Hye Heo, Kyung Ah Han, Jun Hwa Hong, Hyun-Ae Seo, Eun-Gyoung Hong, Jae Myung Yu, Hye Seung Jung, and Bong-Soo Cha
- Subjects
cardiovascular diseases ,diabetes mellitus, type 2 ,insulin resistance ,sodium-glucose transporter 2 inhibitors ,thiazolidinediones ,Diseases of the endocrine glands. Clinical endocrinology ,RC648-665 - Abstract
Background This study assessed the efficacy and safety of triple therapy with pioglitazone 15 mg add-on versus placebo in patients with type 2 diabetes mellitus (T2DM) inadequately controlled with metformin and dapagliflozin. Methods In this multicenter, double-blind, randomized, phase 3 study, patients with T2DM with an inadequate response to treatment with metformin (≥1,000 mg/day) plus dapagliflozin (10 mg/day) were randomized to receive additional pioglitazone 15 mg/day (n=125) or placebo (n=125) for 24 weeks. The primary endpoint was the change in glycosylated hemoglobin (HbA1c) levels from baseline to week 24 (ClinicalTrials.gov identifier: NCT05101135). Results At week 24, the adjusted mean change from baseline in HbA1c level compared with placebo was significantly greater with pioglitazone treatment (–0.47%; 95% confidence interval, –0.61 to –0.33; P
- Published
- 2024
- Full Text
- View/download PDF
3. Hashimoto Thyroiditis and Mortality in Patients with Differentiated Thyroid Cancer: The National Epidemiologic Survey of Thyroid Cancer in Korea and Meta-Analysis
- Author
-
Injung Yang, Jae Myung Yu, Hye Soo Chung, Yoon Jung Kim, Yong Kyun Roh, Min Kyu Choi, Sung-ho Park, Young Joo Park, and Shinje Moon
- Subjects
thyroid neoplasms ,mortality ,hashimoto disease ,Diseases of the endocrine glands. Clinical endocrinology ,RC648-665 - Abstract
Background Many studies have shown that Hashimoto’s thyroiditis (HT) acts as a protective factor in differentiated thyroid cancer (DTC), but little is known about its effects on mortality. Therefore, this study was performed to reveal the prognosis of HT on mortality in patients with DTC. Methods This study included two types of research results: retrospective cohort study using the National Epidemiologic Survey of Thyroid cancer (NEST) in Korea and meta-analysis study with the NEST data and eight selected studies. Results Of the 4,398 patients with DTC in NEST, 341 patients (7.8%) died during the median follow-up period of 15 years (interquartile range, 12.3 to 15.6). Of these, 91 deaths (2.1%) were related to DTC. HT was associated with a smaller tumor size and less aggressive DTC. In Cox regression analysis after adjusting for age and sex, patients with HT showed a significantly lower risk of all-cause death (hazard ratio [HR], 0.71; 95% confidence interval [CI], 0.52 to 0.96) and DTC-related death (HR, 0.33; 95% CI, 0.14 to 0.77). The analysis with inverse probability of treatment weight data adjusted for age, sex, and year of thyroid cancer registration showed similar association. The meta-analysis showed that patients with HT showed a lower risk of all-cause mortality (risk ratio [RR], 0.24; 95% CI, 0.13 to 0.47) and thyroid cancer-related mortality (RR, 0.23; 95% CI, 0.13 to 0.40) in comparison with patients without HT. Conclusion This study showed that DTC co-presenting with HT is associated with a low risk of advanced DTC and presents a low risk for all-cause and DTC-related death.
- Published
- 2024
- Full Text
- View/download PDF
4. Efficacy and Safety of Evogliptin Add-on Therapy to Dapagliflozin/Metformin Combinations in Patients with Poorly Controlled Type 2 Diabetes Mellitus: A 24-Week Multicenter Randomized Placebo-Controlled Parallel-Design Phase-3 Trial with a 28-Week Extension
- Author
-
Jun Sung Moon, Il Rae Park, Hae Jin Kim, Choon Hee Chung, Kyu Chang Won, Kyung Ah Han, Cheol-Young Park, Jong Chul Won, Dong Jun Kim, Gwan Pyo Koh, Eun Sook Kim, Jae Myung Yu, Eun-Gyoung Hong, Chang Beom Lee, and Kun-Ho Yoon
- Subjects
dapagliflozin ,diabetes mellitus, type 2 ,dipeptidyl-peptidase iv inhibitors ,drug therapy, combination ,metformin ,Diseases of the endocrine glands. Clinical endocrinology ,RC648-665 - Abstract
Background This study investigates the long-term efficacy and safety of evogliptin add-on therapy in patients with inadequately controlled type 2 diabetes mellitus (T2DM) previously received dapagliflozin and metformin (DAPA/MET) combination. Methods In this multicenter randomized placebo-controlled phase 3 trial, patients with glycosylated hemoglobin (HbA1c) levels 7.0% to 10.5% (n=283) previously used DAPA 10 mg plus MET (≥1,000 mg) were randomly assigned to the evogliptin 5 mg once daily or placebo group (1:1). The primary endpoint was the difference in the HbA1c level from baseline at week 24, and exploratory endpoints included the efficacy and safety of evogliptin over 52 weeks (trial registration: ClinicalTrials.gov NCT04170998). Results Evogliptin add-on to DAPA/MET therapy was superior in HbA1c reduction compared to placebo at weeks 24 and 52 (least square [LS] mean difference, –0.65% and –0.55%; 95% confidence interval [CI], –0.79 to –0.51 and –0.71 to –0.39; P
- Published
- 2023
- Full Text
- View/download PDF
5. Association between body composition and the risk of mortality in the obese population in the United States
- Author
-
Heeso Lee, Hye Soo Chung, Yoon Jung Kim, Min Kyu Choi, Yong Kyun Roh, Jae Myung Yu, Chang-Myung Oh, Joon Kim, and Shinje Moon
- Subjects
sarcopenia ,obesity ,muscle ,obesity paradox ,mortality ,Diseases of the endocrine glands. Clinical endocrinology ,RC648-665 - Abstract
BackgroundRecent studies have presented the concept of the obesity paradox, suggesting that individuals with obesity have a lower risk of death than those without obesity. This paradox may arise because body mass index (BMI) alone is insufficient to understand body composition accurately. This study investigated the relationship between fat and muscle mass and the risk of mortality in individuals with overweight/obesity.MethodsWe used data from the National Health and Nutrition Examination Survey (NHANES) from 1999 to 2006 and 2011 to 2018, which were linked to mortality information obtained from the National Death Index. Multiple Cox regression analyses were performed to estimate mortality risk. Subgroup analysis was conducted using propensity score-matched (PSM) data for age, sex, and race/ethnicity.ResultsThis study included 16,555 participants who were overweight/obese (BMI≥25 kg/m2). An increase in appendicular skeletal muscle mass index was associated with a lower mortality risk (hazard ratio [HR]: 0.856; 95% confidence interval [CI]: 0.802–0.915). This finding was consistent with the subgroup analysis of the PSM data. Contrastingly, a high fat mass index was associated with an increased risk of mortality. Sarcopenic overweight/obesity was significantly associated with high mortality compared to obesity without sarcopenia (HR: 1.612, 95%CI: 1.328–1.957). This elevated risk was significant in both age- and sex-based subgroups. This finding was consistent with the subgroup analysis using PSM data.ConclusionIn contrast to the obesity paradox, a simple increase in BMI does not protect against mortality. Instead, low body fat and high muscle mass reduce mortality risk.
- Published
- 2023
- Full Text
- View/download PDF
6. Smoking and passive smoking increases mortality through mediation effect of cadmium exposure in the United States
- Author
-
Joon Kim, Hangyul Song, Junghoon Lee, Yoon Jung Kim, Hye Soo Chung, Jae Myung Yu, Gyuho Jang, Raekil Park, Wankyo Chung, Chang-Myung Oh, and Shinje Moon
- Subjects
Medicine ,Science - Abstract
Abstract Cigarette smoking is one of the leading causes of preventable and premature death worldwide. Even worse, many people are generally exposed to passive smoking, which leads to several respiratory diseases and related mortalities. Considering, more than 7000 compounds are included in cigarettes, their combustion results intoxicants that have deleterious effects on health. However, there is a lack of research analyzing the effects of smoking and passive smoking on all-cause and disease-specific mortality through its chemical compounds including heavy metals. Thus, this study aimed to evaluate the effect of smoking and passive smoking on all-cause and disease-specific mortality mediated by cadmium, one of the representative smoking-related heavy metals using data from the National Health and Nutrition Examination Survey (NHANES) 1999–2018 in the United States. We found that current smoking and passive smoking was related to increased risk of all-cause, CVD-related, and cancer-related mortality. Notably, passive smoking showed a synergistic effect with smoking status on the risk of mortality. In particular, current smokers with passive smoking had the highest risk of all-cause and disease-specific deaths. In addition, the accumulation of cadmium in the blood due to smoking and passive smoking mediates the increased risk of all-cause mortality. Further studies are needed to monitor and treat cadmium toxicity to improve smoking-related mortality rates.
- Published
- 2023
- Full Text
- View/download PDF
7. A Real-World Study of Long-Term Safety and Efficacy of Lobeglitazone in Korean Patients with Type 2 Diabetes Mellitus
- Author
-
Bo-Yeon Kim, Hyuk-Sang Kwon, Suk Kyeong Kim, Jung-Hyun Noh, Cheol-Young Park, Hyeong-Kyu Park, Kee-Ho Song, Jong Chul Won, Jae Myung Yu, Mi Young Lee, Jae Hyuk Lee, Soo Lim, Sung Wan Chun, In-Kyung Jeong, Choon Hee Chung, Seung Jin Han, Hee-Seok Kim, Ju-Young Min, and Sungrae Kim
- Subjects
diabetes mellitus ,type 2 ,lobeglitazone ,observational study ,thiazolidinediones ,Diseases of the endocrine glands. Clinical endocrinology ,RC648-665 - Abstract
Background Thiazolidinediones (TZDs) have been associated with various safety concerns including weight gain, bladder cancer, and congestive heart failure (CHF). This study evaluated the efficacy and safety of lobeglitazone, a novel TZD in patients with type 2 diabetes mellitus (T2DM) in real practice. Methods In this non-interventional, multi-center, retrospective, and observational study conducted at 15 tertiary or secondary referral hospitals in Korea, a total of 2,228 patients with T2DM who received lobeglitazone 0.5 mg for more than 1 year were enrolled. Results Overall adverse events (AEs) occurred in 381 patients (17.10%) including edema in 1.97% (n=44). Cerebrovascular and cardiovascular diseases were identified in 0.81% (n=18) and 0.81% (n=18), respectively. One case of CHF was reported as an AE. Edema occurred in 1.97% (n=44) of patients. Hypoglycemia occurred in 2.47% (n=55) of patients. Fracture occurred in 1.17% (n=26) of all patients. Lobeglitazone significantly decreased HbA1c level, resulting in a mean treatment difference of −1.05%± 1.35% (P
- Published
- 2022
- Full Text
- View/download PDF
8. Association between body shape index and risk of mortality in the United States
- Author
-
Heysoo Lee, Hye Soo Chung, Yoon Jung Kim, Min Kyu Choi, Yong Kyun Roh, Wankyo Chung, Jae Myung Yu, Chang-Myung Oh, and Shinje Moon
- Subjects
Medicine ,Science - Abstract
Abstract The body mass index (BMI) neither differentiates fat from lean mass nor does it consider adipose tissue distribution. In contrast, the recently introduced z-score of the log-transformed A Body Shape Index (LBSIZ) can be applied to measure obesity using waist circumference (WC), height, and weight. We aimed to investigate the association between LBSIZ and mortality. We used data from the National Health and Nutrition Examination Survey 1999–2014 and linked the primary dataset to death certificate data from the National Death Index with mortality follow-up through December 31, 2015. A multiple Cox regression analysis was performed to evaluate the hazard ratio (HR) of all-cause and cardiovascular disease (CVD) mortalities with adjustment for baseline characteristics. LBSIZ, WC, and BMI showed positive association with total fat percentage (P
- Published
- 2022
- Full Text
- View/download PDF
9. The Relationship Between Nocturia and Mortality: Data From the National Health and Nutrition Examination Survey
- Author
-
Shinje Moon, Yoon Jung Kim, Hye Soo Chung, Jae Myung Yu, Il In Park, Sung Gon Park, Sahyun Pak, Ohseong Kwon, Young Goo Lee, and Sung Tae Cho
- Subjects
nocturia ,mortality ,urinary bladder ,lower urinary tract symptoms ,nutrition surveys ,epidemiology ,Diseases of the genitourinary system. Urology ,RC870-923 - Abstract
Purpose We investigated the relationship between nocturia and mortality risk in the United States. Methods Data were obtained from the National Health and Nutrition Examination Survey 2005–2010. Mortality data were obtained by linking the primary database to death certificate data found in the National Death Index with mortality follow-up up to December 31, 2015. Nocturia was defined based on symptoms reported in the symptom questionnaire. We categorized patients into 2 groups: mild nocturia (2–3 voids/night) and moderate-to severe nocturia (≥4 voids/night). Multiple Cox regression analyses were performed with adjustment for confounding variables at the baseline survey. Results This study included 9,892 adults (4,758 men, 5,134 women). Nocturia occurred in 3,314 individuals (33.5%). Nocturia was significantly associated with all-cause mortality (hazard ratio [HR], 1.23; 95% confidence interval [CI], 1.10–1.39) and cardiovascular disease (CVD) mortality (HR, 1.55; 95% CI, 1.19–2.01). Moreover, the mortality risk increased with increasing nocturia severity. Further analysis with propensity score matching showed that nocturia was still significantly associated with all-cause mortality and CVD mortality. In subgroup analysis according to sex, nocturia was significantly associated with allcause mortality and CVD mortality in men. In women, moderate-to-severe nocturia was significantly associated with allcause mortality and CVD mortality. In subgroup analysis according to cardio-metabolic diseases, nocturia was associated with CVD mortality in patients with diabetes mellitus, hypertension, dyslipidemia, or CVD at baseline. In subgroup analysis of patients without diabetes mellitus, hypertension or CVD, nocturia was significantly associated with all-cause mortality. Conclusions Nocturia was significantly associated with mortality in men and women after adjusting for major confounding factors.
- Published
- 2022
- Full Text
- View/download PDF
10. Framingham Risk Score Assessment in Subjects with Pre-diabetes and Diabetes: A Cross-Sectional Study in Korea
- Author
-
Hyuk Sang Kwon, Kee Ho Song, Jae Myung Yu, Dong Sun Kim, Ho Sang Shon, Kyu Jeung Ahn, Sung Hee Choi, Seung Hyun Ko, Won Kim, Kyoung Hwa Lee, Il Seong Nam-Goong, and Tae Sun Park
- Subjects
cardiovascular diseases ,diabetes mellitus ,risk assessment ,Diseases of the endocrine glands. Clinical endocrinology ,RC648-665 - Abstract
Background : This study aimed to evaluate cardiovascular risk in subjects with pre-diabetes and diabetes in Korea. Methods : In this pan-Korean, non-interventional, cross-sectional study, data were collected from medical records of 10 hospitals between November 2013 and June 2014. Subjects (aged ≥40 years) with medical records of dysglycemia and documentation of total cholesterol level, high-density lipoprotein cholesterol level, systolic blood pressure, and smoking status in the past 6 months were included. The primary endpoint was to determine the Framingham risk score (FRS). The relationships between FRS and cardiovascular risk factors, glycated hemoglobin, and insulin usage were determined by multiple linear regression analyses. Results : Data from 1,537 subjects with pre-diabetes (n=1,025) and diabetes (n=512) were analyzed. The mean FRS (mean±standard deviation) in subjects with pre-diabetes/diabetes was 13.72±8.77. FRS was higher in subjects with diabetes than pre-diabetes (P
- Published
- 2021
- Full Text
- View/download PDF
11. Efficacy and Safety of the New Appetite Suppressant, Liraglutide: A Meta-Analysis of Randomized Controlled Trials
- Author
-
Shinje Moon, Jibeom Lee, Hye Soo Chung, Yoon Jung Kim, Jae Myung Yu, Sung Hoon Yu, and Chang-Myung Oh
- Subjects
liraglutide ,glucagon-like peptide 1 ,obesity ,metabolic syndrome ,meta-analysis ,Diseases of the endocrine glands. Clinical endocrinology ,RC648-665 - Abstract
Background Obesity is a chronic disease associated with metabolic diseases such as diabetes and cardiovascular disease. Since the U.S. Food and Drug Administration approved liraglutide as an anti-obesity drug for nondiabetic patients in 2014, it has been widely used for weight control in overweight and obese people. This study aimed to systematically analyze the effects of liraglutide on body weight and other cardiometabolic parameters. Methods We investigated articles from PubMed, EMBASE, and the Cochrane Library to search randomized clinical trials that examined body weight changes with liraglutide treatment. Results We included 31 studies with 8,060 participants for this meta-analysis. The mean difference (MD) between the liraglutide group and the placebo group was −4.19 kg (95% confidence interval [CI], −4.84 to −3.55), with a −4.16% change from the baseline (95% CI, −4.90 to −3.43). Liraglutide treatment correlated with a significantly reduced body mass index (MD: −1.55; 95% CI, −1.76 to −1.34) and waist circumference (MD: −3.11 cm; 95% CI, −3.59 to −2.62) and significantly decreased blood pressure (systolic blood pressure, MD: −2.85 mm Hg; 95% CI, −3.36 to −2.35; diastolic blood pressure, MD: −0.66 mm Hg; 95% CI, −1.02 to −0.30), glycated hemoglobin (MD: −0.40%; 95% CI, −0.49 to −0.31), and low-density lipoprotein cholesterol (MD: −2.91 mg/dL; 95% CI, −5.28 to −0.53; MD: −0.87% change from baseline; 95% CI, −1.17 to −0.56). Conclusion Liraglutide is effective for weight control and can be a promising drug for cardiovascular protection in overweight and obese people.
- Published
- 2021
- Full Text
- View/download PDF
12. Efficacy and Safety of Omega-3 Fatty Acids in Patients Treated with Statins for Residual Hypertriglyceridemia: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial
- Author
-
Ji Eun Jun, In-Kyung Jeong, Jae Myung Yu, Sung Rae Kim, In Kye Lee, Kyung-Ah Han, Sung Hee Choi, Soo-Kyung Kim, Hyeong Kyu Park, Ji-Oh Mok, Yong-ho Lee, Hyuk-Sang Kwon, So Hun Kim, Ho-Cheol Kang, Sang Ah Lee, Chang Beom Lee, Kyung Mook Choi, Sung-Ho Her, Won Yong Shin, Mi-Seung Shin, Hyo-Suk Ahn, Seung Ho Kang, Jin-Man Cho, Sang-Ho Jo, Tae-Joon Cha, Seok Yeon Kim, Kyung Heon Won, Dong-Bin Kim, Jae Hyuk Lee, and Moon-Kyu Lee
- Subjects
atorvastatin ,fatty acids, omega-3 ,hypertriglyceridemia ,Diseases of the endocrine glands. Clinical endocrinology ,RC648-665 - Abstract
BackgroundCardiovascular risk remains increased despite optimal low density lipoprotein cholesterol (LDL-C) level induced by intensive statin therapy. Therefore, recent guidelines recommend non-high density lipoprotein cholesterol (non-HDL-C) as a secondary target for preventing cardiovascular events. The aim of this study was to assess the efficacy and tolerability of omega-3 fatty acids (OM3-FAs) in combination with atorvastatin compared to atorvastatin alone in patients with mixed dyslipidemia.MethodsThis randomized, double-blind, placebo-controlled, parallel-group, and phase III multicenter study included adults with fasting triglyceride (TG) levels ≥200 and
- Published
- 2020
- Full Text
- View/download PDF
13. Association between Serum Selenium Level and the Presence of Diabetes Mellitus: A Meta-Analysis of Observational Studies
- Author
-
Juno Kim, Hye Soo Chung, Min-Kyu Choi, Yong Kyun Roh, Hyung Joon Yoo, Jung Hwan Park, Dong Sun Kim, Jae Myung Yu, and Shinje Moon
- Subjects
antioxidants ,diabetes mellitus ,selenium ,trace elements ,Diseases of the endocrine glands. Clinical endocrinology ,RC648-665 - Abstract
BackgroundEpidemiological studies have suggested an association between selenium (Se) and diabetes mellitus (DM). However, different studies have reported conflicting results. Therefore, we performed a comprehensive meta-analysis to clarify the impact of Se on DM.MethodsWe searched the PubMed database for studies on the association between Se and DM from inception to June 2018.ResultsTwenty articles evaluating 47,930 participants were included in the analysis. The meta-analysis found that high levels of Se were significantly associated with the presence of DM (pooled odds ratios [ORs], 1.88; 95% confidence interval [CI], 1.44 to 2.45). However, significant heterogeneity was found (I2=82%). Subgroup analyses were performed based on the Se measurement methods used in each study. A significant association was found between high Se levels and the presence of DM in the studies that used blood (OR, 2.17; 95% CI, 1.60 to 2.93; I2=77%), diet (OR, 1.61; 95% CI, 1.10 to 2.36; I2=0%), and urine (OR, 1.49; 95% CI, 1.02 to 2.17; I2=0%) as samples to estimate Se levels, but not in studies on nails (OR, 1.24; 95% CI, 0.52 to 2.98; I2=91%). Because of significant heterogeneity in the studies with blood, we conducted a sensitivity analysis and tested the publication bias. The results were consistent after adjustment based on the sensitivity analysis as well as the trim and fill analysis for publication bias.ConclusionThis meta-analysis demonstrates that high levels of Se are associated with the presence of DM. Further prospective and randomized controlled trials are warranted to elucidate the link better.
- Published
- 2019
- Full Text
- View/download PDF
14. The Association Between Obesity and the Nocturia in the U.S. Population
- Author
-
Shinje Moon, Hye Soo Chung, Jae Myung Yu, Kwang Jin Ko, Don Kyoung Choi, Ohseong Kwon, Young Goo Lee, and Sung Tae Cho
- Subjects
Obesity ,Body mass index ,Nocturia ,Diseases of the genitourinary system. Urology ,RC870-923 - Abstract
Purpose We aimed to investigate the association of obesity with nocturia using a nationally representative sample of adults from the National Health and Nutrition Examination Survey (NHANES) between 2005 and 2012. Methods A total of 14,135 participants were included in this study. We performed a multivariate logistic regression analysis to find the odds ratio (OR) of obesity for nocturia. Furthermore, the OR of BMI for nocturia was analyzed using restricted cubic splines (RCS) with five knots. We conducted subgroup analysis according to age, sex, hypertension, and diabetes mellitus (DM) and further analysis with 1:1 matching data with propensity score. Results The participants who had body mass index (BMI) above 30 kg/m2 had a significantly higher OR for nocturia (OR, 1.39; 95% CI, 1.28–1.50) than those without obesity. RCS showed a dose-dependent relationship between BMI and OR for nocturia. Subgroup analysis by age, sex, hypertension, and DM showed similar results. Further analysis with 1:1 matching data showed a significant association of obesity with the prevalence of nocturia (OR, 1.25; 95% CI, 1.10–1.41). Conclusions This study reported that obesity was significant association with the prevalence of nocturia with dose-dependent manner, regardless of age, sex, hypertension, and DM after taking major confounding factors into account.
- Published
- 2019
- Full Text
- View/download PDF
15. Efficacy and Safety of Voglibose Plus Metformin in Patients with Type 2 Diabetes Mellitus: A Randomized Controlled Trial
- Author
-
Tae Jung Oh, Jae Myung Yu, Kyung Wan Min, Hyun Shik Son, Moon Kyu Lee, Kun Ho Yoon, Young Duk Song, Joong Yeol Park, In Kyung Jeong, Bong Soo Cha, Yong Seong Kim, Sei Hyun Baik, In Joo Kim, Doo Man Kim, Sung Rae Kim, Kwan Woo Lee, Jeong Hyung Park, In Kyu Lee, Tae Sun Park, Sung Hee Choi, and Sung Woo Park
- Subjects
diabetes mellitus, type 2 ,metformin ,voglibose ,Diseases of the endocrine glands. Clinical endocrinology ,RC648-665 - Abstract
BackgroundCombination of metformin to reduce the fasting plasma glucose level and an α-glucosidase inhibitor to decrease the postprandial glucose level is expected to generate a complementary effect. We compared the efficacy and safety of a fixed-dose combination of voglibose plus metformin (vogmet) with metformin monotherapy in drug-naïve newly-diagnosed type 2 diabetes mellitus.MethodsA total of 187 eligible patients aged 20 to 70 years, with a glycosylated hemoglobin (HbA1c) level of 7.0% to 11.0%, were randomized into either vogmet or metformin treatments for 24 weeks. A change in the HbA1c level from baseline was measured at week 24.ResultsThe reduction in the levels of HbA1c was −1.62%±0.07% in the vogmet group and −1.31%±0.07% in the metformin group (P=0.003), and significantly more vogmet-treated patients achieved the target HbA1c levels of
- Published
- 2019
- Full Text
- View/download PDF
16. Analyzing the Factors Associated With Nocturia in Older People in the United States
- Author
-
Joo Seop Kim, Hye Soo Chung, Jae Myung Yu, Sung Tae Cho, Shinje Moon, Hyung Joon Yoo, and the Geriatric Syndromes Society
- Subjects
Obesity ,Nocturia ,Aged ,Medicine ,Geriatrics ,RC952-954.6 - Abstract
Background: The risk factors of nocturia in older adults remain unclear. We aimed to investigate factors associated with nocturia using the National Health and Nutrition Examination Survey (NHANES) data. Methods: Among 40,790 participants, 4,698 participants aged ≥65 years were included from the NHANES dataset between 2005 and 2012. A multivariate logistic regression analysis was performed to determine the odds ratio (OR) for nocturia. A subgroup analysis was conducted based on sex and underlying diseases. Results: In the multivariate logistic regression model, obesity (OR, 1.46; 95% confidence interval [CI], 1.28–1.68), hypertension (OR, 1.28; 95% CI, 1.07–1.52), and diabetes mellitus (DM) (OR, 1.27; 95% CI, 1.11–1.45) were significantly associated with nocturia. These factors were associated with nocturia regardless of sex. In a subgroup of participants with hypertension, obesity (OR, 1.44; 95% CI, 1.25–1.67) and DM (OR, 1.26; 95% CI, 1.09–1.45) were associated with nocturia. In the additional analysis on patients with DM, nocturia was associated with obesity (OR, 1.33; 95% CI, 1.06–1.67) and duration of DM (OR, 1.02; 95% CI, 1.01–1.03). Conclusion: This study demonstrated that hypertension, DM, and obesity were significantly associated with the prevalence of nocturia in older adult patients regardless of sex. In particular, obesity was associated with nocturia in every subgroup analysis.
- Published
- 2018
- Full Text
- View/download PDF
17. Associations between Hashimoto Thyroiditis and Clinical Outcomes of Papillary Thyroid Cancer: A Meta-Analysis of Observational Studies
- Author
-
Shinje Moon, Hye Soo Chung, Jae Myung Yu, Hyung Joon Yoo, Jung Hwan Park, Dong Sun Kim, and Young Joo Park
- Subjects
Hashimoto disease ,Thyroid cancer, papillary ,Prognosis ,Diseases of the endocrine glands. Clinical endocrinology ,RC648-665 - Abstract
BackgroundEpidemiological studies have suggested an association between Hashimoto thyroiditis (HT) and papillary thyroid cancer (PTC) development. Other studies, however, have reported a protective role of HT against PTC progression. Through this updated meta-analysis, we aimed to clarify the effects of HT on the progression of PTC.MethodsWe searched citation databases, including PubMed and Embase, for relevant studies from inception to September 2017. From these studies, we calculated the pooled odds ratios (ORs) of clinicopathologic features and the relative risk (RR) of PTC recurrence with 95% confidence intervals (CIs) using the Mantel-Haenszel method. Additionally, the Higgins I2 statistic was used to test for heterogeneity.ResultsThe meta-analysis included 71 published studies with 44,034 participants, among whom 11,132 had HT. We observed negative associations between PTC with comorbid HT and extrathyroidal extension (OR, 0.74; 95% CI, 0.68 to 0.81), lymph node metastasis (OR, 0.82; 95% CI, 0.72 to 0.94), distant metastasis (OR, 0.49; 95% CI, 0.32 to 0.76), and recurrence (RR, 0.50; 95% CI, 0.41 to 0.61).ConclusionIn this meta-analysis, PTC patients with HT appeared to exhibit more favorable clinicopathologic characteristics and a better prognosis than those without HT.
- Published
- 2018
- Full Text
- View/download PDF
18. The impact of urinary incontinence on falls: A systematic review and meta-analysis.
- Author
-
Shinje Moon, Hye Soo Chung, Yoon Jung Kim, Sung Jin Kim, Ohseong Kwon, Young Goo Lee, Jae Myung Yu, and Sung Tae Cho
- Subjects
Medicine ,Science - Abstract
ObjectivePrevious studies on the association between urinary incontinence (UI) and falls have reported conflicting results. We, therefore, aimed to evaluate and clarify this association through a systematic review and meta-analysis of relevant studies.MethodsWe performed a literature search for relevant studies in databases including PubMed and EMBASE from inception up to December 13, 2020, using several search terms related to UI and falls. Based on the data reported in these studies, we calculated the pooled odds ratios (ORs) for falls and the corresponding 95% confidence intervals (CIs) using the Mantel-Haenszel method.ResultsThis meta-analysis included 38 articles and a total of 230,129 participants. UI was significantly associated with falls (OR, 1.62; 95% CI, 1.45-1.83). Subgroup analyses based on the age and sex of the participants revealed a significant association between UI and falls in older (≥65 years) participants (OR, 1.59; 95% CI, 1.31-1.93), and in both men (OR, 1.88; 95% CI, 1.57-2.25) and women (OR, 1.41; 95% CI, 1.29-1.54). Subgroup analysis based on the definition of falls revealed a significant association between UI and falls (≥1 fall event) (OR, 1.61; 95% CI, 1.42-1.82) and recurrent falls (≥2 fall events) (OR, 1.63; 95% CI, 1.49-1.78). According to the UI type, a significant association between UI and falls was observed in patients with urgency UI (OR, 1.76; 95% CI, 1.15-1.70) and those with stress UI (OR, 1.73; 95% CI, 1.39-2.15).ConclusionsThis meta-analysis, which was based on evidence from a review of the published literature, clearly demonstrated that UI is an important risk factor for falls in both general and older populations.
- Published
- 2021
- Full Text
- View/download PDF
19. Z-score of the log-transformed A Body Shape Index predicts low muscle mass in population with abdominal obesity: The U.S. and Korea National Health and Nutrition Examination Survey.
- Author
-
Shinje Moon, Yoon Jung Kim, Jae Myung Yu, Jun Goo Kang, and Hye Soo Chung
- Subjects
Medicine ,Science - Abstract
Background and objectiveSarcopenic obesity is associated with a higher risk of cardiometabolic disease and mortality than either sarcopenia or obesity alone. However, no study has investigated body shape indices for the assessment of sarcopenia in obese populations. Thus, this study aimed to evaluate the accuracy of body shape indices to assess sarcopenia in nationally representative populations with abdominal obesity.MethodsData from the U.S. National Health and Nutrition Examination Survey (U.S. NHANES) 1999-2006 and Korea NHANES (KNHANES) 2008-2011 were assessed. The association between Body Shape Index and sarcopenia was analyzed using a receiver operating characteristic curve. The Z-score of the log-transformed A Body Shape Index (LBSIZ) cut-off value was defined as that with the highest score of the Youden's index. Changes in odds ratios (OR) for sarcopenia were investigated using restricted cubic spline (RCS) plots.ResultsThis study included 8,013 American and 4,859 Korean adults with abdominal obesity. The overall area under the curve (AUC) of LBSIZ for sarcopenia was 0.816 (95% CI: 0.794-0.838) in U.S. NHANES and 0.822 (95% CI: 0.799-0.844) in KNHANES, which was higher than that of the body roundness index, conicity index, and waist to height ratio (p with DeLong's test ConclusionThe increased LBSIZ could function as a reliable and cost-effective screening tool for assessing low muscle mass in populations with abdominal obesity.
- Published
- 2020
- Full Text
- View/download PDF
20. Association of Z-Score of the Log-Transformed A Body Shape Index with Cardiovascular Disease in People Who Are Obese but Metabolically Healthy: The Korea National Health and Nutrition Examination Survey 2007-2010
- Author
-
Wankyo Chung, Jung Hwan Park, Ohk-Hyun Ryu, Jae Myung Yu, Hyung Joon Yoo, and Shinje Moon
- Subjects
Obesity ,Metabolically benign ,Body mass index ,Body constitution ,Cardiovascular disease ,Diseases of the endocrine glands. Clinical endocrinology ,RC648-665 - Abstract
Background: We aimed at evaluating the effect of the z-score of the log-transformed A Body Shape Index (LBSIZ) on cardiovascular disease (CVD) outcomes according to obesity phenotype. Methods: Data were collected from the Korea National Health and Nutrition Examination Survey conducted from 2007 to 2010. Obesity was defined as a body mass index above 25 kg/m² and metabolic abnormality was defined as the presence of two or more metabolic risk factors of the Adult Treatment Panel III definition. The participants were classified by obesity and metabolic healthy status: metabolically healthy non-obese (MHNO), metabolically healthy obese (MHO), metabolically unhealthy non-obese (MUNO), and metabolically unhealthy obese (MUO). Each group was further classified into three groups based on the tertile of LBSIZ. A multivariate logistic regression analysis with adjustment for age, sex, smoking status, income, education level, physical activities, alcohol, and energy intake was conducted to evaluate the odds ratio (OR) for CVD events. Results: In the multivariate logistic regression model, MHO participants who are within the third tertile of LBSIZ had a significantly higher OR for CVD events, whereas those who are within the first and second tertile of LBSIZ were not at high risk of developing CVDs compared to MHNO participants who are within the first tertile of LBSIZ. In addition, a similar increase in the OR was observed in MUNO or MUO participants. Conclusion: LBSIZ had the lowest risk for CVDs in the first tertile of LBSIZ and a linear relationship with all its tertiles in MHO, MUNO, and MUO participants.
- Published
- 2018
- Full Text
- View/download PDF
21. Intermittent High Glucose Enhances the Proliferation of Rat Aortic Vascular Smooth Muscle Cells More Than Constant High Glucose via the Mitogen-Activated Protein Kinase Pathway
- Author
-
Sung Hoon Yu, Hyung Joon Yoo, Dong Hyun Kang, Shin Je Moon, and Jae Myung Yu
- Subjects
Intermittent high glucose ,Vascular smooth muscle cell ,Mitogen-activated protein kinase ,Apoptosis ,Medicine ,Geriatrics ,RC952-954.6 - Abstract
Background : The acute glucose fluctuations in diabetes can be a risk factor of cardiovascular events. Nonetheless, the mechanism of action of intermittent hyperglycemia on the proliferation of vascular smooth muscle cells (VSMCs) is poorly understood. We compared the effects of exposure to constant and intermittent hyperglycemia on in vitro proliferation of aortic VSMCs from obese diabetic rats. Methods : VSMCs from Otsuka Long-Evans Tokushima Fatty (OLETF) rats were incubated for 72 hours with different glucose concentrations: a constant normal-glucose medium (4.8 mM), constant high-glucose medium (24.5 mM), normal- and high-glucose media alternating every 12 hours, and mannose (12.0 mM; an osmotic control for high glucose levels). The proliferation of VSMCs was analyzed by a 3-[4,5-dimethylthiazol-2-yl]-diphenyltetrazolium bromide (MTT) assay. The molecular mechanism (including phospho-p44/42 mitogen-activated protein kinase [MAPK], mitogen-activated protein kinase kinase-1/2 (MEK1/2), Protein kinase B (Akt), and the apoptosis pathway) was then studied. Results : We detected enhanced proliferation of VSMCs incubated with the constant or intermittent high-glucose medium using the MTT assay (p
- Published
- 2017
- Full Text
- View/download PDF
22. Beneficial Effects of Time-Restricted Eating on Metabolic Diseases: A Systemic Review and Meta-Analysis
- Author
-
Shinje Moon, Jiseung Kang, Sang Hyun Kim, Hye Soo Chung, Yoon Jung Kim, Jae Myung Yu, Sung Tae Cho, Chang-Myung Oh, and Tae Kim
- Subjects
time-restricted eating ,circadian rhythm ,obesity ,metabolic syndrome ,meta-analysis ,Nutrition. Foods and food supply ,TX341-641 - Abstract
Various behavioral and physiological pathways follow a pre-determined, 24 hour cycle known as the circadian rhythm. Metabolic homeostasis is regulated by the circadian rhythm. Time-restricted eating (TRE) is a type of intermittent fasting based on the circadian rhythm. In this study, we aim to analyze systemically the effects of TRE on body weight, body composition, and other metabolic parameters. We reviewed articles from PubMed, EMBASE, and the Cochrane Library to identify clinical trials that compared TRE to a regular diet. We included 19 studies for meta-analysis. Participants following TRE showed significantly reduced body weight (mean difference (MD), −0.90; 95% confidence interval (CI): −1.71 to −0.10) and fat mass (MD: −1.58, 95% CI: −2.64 to −0.51), while preserving fat-free mass (MD, −0.24; 95% CI: −1.15 to 0.67). TRE also showed beneficial effects on cardiometabolic parameters such as blood pressure (systolic BP, MD, −3.07; 95% CI: −5.76 to −0.37), fasting glucose concentration (MD, −2.96; 95% CI, −5.60 to −0.33), and cholesterol profiles (triglycerides, MD: −11.60, 95% CI: −23.30 to −0.27). In conclusion, TRE is a promising therapeutic strategy for controlling weight and improving metabolic dysfunctions in those who are overweight or obese. Further large-scale clinical trials are needed to confirm these findings and the usefulness of TRE.
- Published
- 2020
- Full Text
- View/download PDF
23. Association between metabolic parameters and glomerular hyperfiltration in a representative Korean population without chronic kidney disease.
- Author
-
Sangmo Hong, Yun Mi Choi, Sung-Hee Ihm, Dooman Kim, Moon-Gi Choi, Jae Myung Yu, and Eun-Gyoung Hong
- Subjects
Medicine ,Science - Abstract
AimsTo investigate associations of glomerular hyperfiltration with other metabolic factors in a nationally representative dataset.MethodsWe analyzed cross-sectional data from 15,918 subjects with estimated glomerular filtration rate (eGFR) >60 ml/min/1.73 m2 and urine albumin creation ratio (ACR) ResultsPrevalence of hyperfiltration was 5.2% and that among normal, prediabetic, and diabetic subjects was 4.9%, 5.6%, and 7.3%, respectively, after adjusting for age, sex, and body weight (p for trend = 0.008). In a multiple logistic regression analysis, hyperfiltration was associated with a body mass index ≥30 kg/m2 [odds ratio (OR) = 3.461, pConclusionsIn a general Korean population, both hyperfiltration and ACR were associated with similar metabolic parameters, and hyperfiltration correlated independently with a high ACR. Longitudinal studies are needed to further explore risks of hyperfiltration and microalbuminuria.
- Published
- 2018
- Full Text
- View/download PDF
24. The cut-off values of surrogate measures for insulin resistance in the Korean population according to the Korean Genome and Epidemiology Study (KOGES).
- Author
-
Bongyoung Kim, Hyun Young Choi, Wonhee Kim, Chiwon Ahn, Juncheol Lee, Jae Guk Kim, Jihoon Kim, Hyungoo Shin, Jae Myung Yu, and Shinje Moon
- Subjects
Medicine ,Science - Abstract
OBJECTIVE:The current methods available for determining insulin resistance are complicated; hence, they are only applicable to small-scale studies. Therefore, this study aimed to classify the characteristics of surrogate measures for insulin resistance and establish valid cut-off values for predicting the development of type 2 diabetes mellitus (DM) in Korean populations. METHODS:This prospective study included 7,643 participants aged 40-69 years from the Ansung-Ansan cohort database (2001-2012). Four surrogate measures, namely homeostasis model assessment-insulin resistance (HOMA-IR), visceral adiposity index (VAI), lipid accumulation product (LAP), and triglycerides and glucose (TyG) index, were analyzed. We analyzed each measure using receiver operating characteristic (ROC) curve for the development of type 2 DM. The cut-off value was determined as the value with the highest Youden index score in the specificity dominant area. RESULTS:The area under the curve (AUC) was 0.566 (95% confidence interval [CI], 0.548-0.583) for HOMA-IR, 0.622 (95% CI, 0.605-0.639) for VAI, 0.642 (95% CI, 0.625-0.658) for LAP, and 0.672 (95% CI, 0.656-0.687) for TyG index. The AUC of TyG index was significantly higher than that of HOMA-IR, VAI, and LAP (p < 0.001). The cut-off value was 2.54 (sensitivity 36.8%; specificity 73.1%; hazard ratio [HR], 1.41, 95% CI, 1.25-1.59) for HOMA-IR, 2.54 (sensitivity 50.4%; specificity 68.8%; HR, 1.75, 95% CI, 1.55-1.96) for VAI, 36.6 (sensitivity 59.2%; specificity 63.9%; HR, 1.87, 95% CI, 1.64-2.14) for LAP, and 4.69 (sensitivity 62.1%; specificity 63.1%; HR, 2.17, 95% CI, 1.92-2.45) for TyG index. CONCLUSIONS:The TyG index was a better predictor for DM than HOMA-IR. VAI and LAP showed the modest predictability for DM. The TyG index could be a useful supplementary method for identifying individuals at risk for insulin resistance and DM development.
- Published
- 2018
- Full Text
- View/download PDF
25. Evaluation of Aldose Reductase, Protein Glycation, and Antioxidant Inhibitory Activities of Bioactive Flavonoids in Matricaria recutita L. and Their Structure-Activity Relationship
- Author
-
Seung Hwan Hwang, Zhiqiang Wang, Yanymee N. Guillen Quispe, Soon Sung Lim, and Jae Myung Yu
- Subjects
Diseases of the endocrine glands. Clinical endocrinology ,RC648-665 - Abstract
The inhibitory activities of Matricaria recutita L. 70% methanol extract were evaluated by isolating and testing 10 of its compounds on rat lens aldose reductase (RLAR), advanced glycation end products (AGEs), and 2,2-diphenyl-1-picrylhydrazyl (DPPH) radical scavenging. Among these compounds, apigenin-7-O-β-D-glucoside, luteolin-7-O-β-D-glucoside, apigenin-7-O-β-D-glucuronide, luteolin-7-O-β-D-glucuronide, 3,5-O-di-caffeoylquinic acid, apigenin, and luteolin showed potent inhibition, and their IC50 values in RLAR were 4.25, 1.12, 1.16, 0.85, 0.72, 1.72, and 1.42 μM, respectively. Furthermore, these compounds suppressed sorbitol accumulation in rat lens under high-glucose conditions, demonstrating their potential to prevent sorbitol accumulation ex vivo. Notably, luteolin-7-O-β-D-glucuronide and luteolin showed antioxidative as well as AGE-inhibitory activities (IC50 values of these compounds in AGEs were 3.39 and 6.01 μM). These results suggest that the M. recutita extract and its constituents may be promising agents for use in the prevention or treatment of diabetic complications.
- Published
- 2018
- Full Text
- View/download PDF
26. Response: Association of Z-Score of the Log-Transformed A Body Shape Index with Cardiovascular Disease in People Who Are Obese but Metabolically Healthy: The Korea National Health and Nutrition Examination Survey 2007-2010 (J Obes Metab Syndr 2018;27:158-65)
- Author
-
Wankyo Chung, Jung Hwan Park, Ohk-Hyun Ryu, Jae Myung Yu, Hyung Joon Yoo, and Shinje Moon
- Subjects
Diseases of the endocrine glands. Clinical endocrinology ,RC648-665 - Published
- 2019
- Full Text
- View/download PDF
27. The influence of physical activity on risk of cardiovascular disease in people who are obese but metabolically healthy.
- Author
-
Shinje Moon, Chang-Myung Oh, Moon-Ki Choi, Yoo-Kyung Park, Sukyung Chun, Minkyung Choi, Jae Myung Yu, and Hyung Joon Yoo
- Subjects
Medicine ,Science - Abstract
The metabolic outcomes of metabolically healthy obesity (MHO) remain controversial. The aim of the present study was to determine the effect of physical activity on the cardiovascular disease (CVD) outcomes of MHO. The study included participants who were followed for 10 years and recruited from the Korean Genome and Epidemiology Study (KoGES), a population-based cohort study. Participants with previously recorded CVDs or cancer, or who had received steroids or anticoagulants at baseline were excluded. A total of 8144 participants (3,942 men and 4,202 women) fulfilled inclusion criteria. In a multivariate Cox regression model adjusted for age and sex, MHO participants were not at elevated risk of CVD compared with their metabolically healthy non-obese (MHNO) counterparts (HR, 1.28; 95% CI, 0.96-1.71), although both the non-obese (HR, 1.50; 95% CI, 1.19-1.90) and obese (HR, 1.85; 95% CI, 1.48-2.30) participants with metabolic abnormalities were at elevated risk. However, in the subgroup analysis by physical activity, physically inactive MHO participants had a significantly higher HR for CVD events compared to active MHNO participants (HR, 1.54; 95% CI, 1.03-2.30), while active MHO participants were not at elevated risk (HR, 1.15; 95% CI, 0.70-1.89). Physically inactive MHO participants had significantly increased risk of CVD compared to physically active MHNO participants whereas physically active MHO participants did not.
- Published
- 2017
- Full Text
- View/download PDF
28. The Effect of an Angiotensin Receptor Blocker on Arterial Stiffness in Type 2 Diabetes Mellitus Patients with Hypertension
- Author
-
Ji Hyun Kim, Su Jin Oh, Jung Min Lee, Eun Gyoung Hong, Jae Myung Yu, Kyung Ah Han, Kyung Wan Min, Hyun Shik Son, and Sang Ah Chang
- Subjects
Angiotensin receptor blocker ,Arterial stiffness ,Diabetes mellitus ,Hypertension ,Diseases of the endocrine glands. Clinical endocrinology ,RC648-665 - Abstract
BackgroundHypertension and type 2 diabetes mellitus are major risk factors for cardiovascular disease. This study analyzed the changes in central aortic waveforms and pulse wave velocity as well as related parameters after treatment with valsartan, an angiotensin II type 1 receptor blocker, in patients with type 2 diabetes and hypertension.MethodsWe used pulse wave analysis to measure central aortic waveform in a total of 98 subjects. In 47 of these patients, pulse wave velocity measurements were obtained before and after 12 weeks of treatment with valsartan.ResultsIn the central aortic waveform analysis, the aortic pulse pressure and augmentation index were significantly decreased after valsartan treatment, as was the aortic pulse wave velocity. Factors contributing to the improvement in pulse wave velocity were the fasting blood glucose and haemoglobin A1c levels.ConclusionShort-term treatment with valsartan improves arterial stiffness in patients with type 2 diabetes and hypertension, and the glucose status at baseline was associated with this effect.
- Published
- 2011
- Full Text
- View/download PDF
29. The intermittent bolus infusions of rapid infusion system caused hypothermia during liver transplantation
- Author
-
Gaab-Soo Kim, Justin Sangwook Ko, Jae Myung Yu, and Ha Yeon Kim
- Subjects
Anesthesiology ,RD78.3-87.3 - Published
- 2013
- Full Text
- View/download PDF
30. Response: The Effect of an Angiotensin Receptor Blocker on Arterial Stiffness in Type 2 Diabetes Mellitus Patients with Hypertension (Diabetes Metab J 2011;35:236-42)
- Author
-
Ji Hyun Kim, Su Jin Oh, Jung Min Lee, Eun Gyoung Hong, Jae Myung Yu, Kyung Ah Han, Kyung Wan Min, Hyun Shik Son, and Sang Ah Chang
- Subjects
Diseases of the endocrine glands. Clinical endocrinology ,RC648-665 - Published
- 2011
- Full Text
- View/download PDF
31. Anagliptin twice‐daily regimen improves glycaemic variability in subjects with type 2 diabetes: A d <scp>ouble‐blind</scp> , randomized controlled trial
- Author
-
Yong-Ho, Lee, Doo-Man, Kim, Jae Myung, Yu, Kyung Mook, Choi, Sin Gon, Kim, Kang Seo, Park, Hyun-Shik, Son, Choon Hee, Chung, Kyu Jeung, Ahn, Soon Hee, Lee, Ki-Ho, Song, Su Kyoung, Kwon, Hyeong Kyu, Park, Kyu Chang, Won, and Hak Chul, Jang
- Subjects
Endocrinology ,Endocrinology, Diabetes and Metabolism ,Internal Medicine - Abstract
Determine whether the twice daily (BID) regimen is superior to the once daily (QD) regimen for managing glycemic variability by comparing the effects of anagliptin 100 mg BID versus sitagliptin 100 mg QD.A double-blinded, randomized, multicenter study was performed in 89 patients with type 2 diabetes treated with metformin alone (6.5%HbA1c 8.5%). Subjects were randomly assigned to anagliptin 100 mg BID or sitagliptin 100 mg QD in a 1:1 ratio for 12 weeks. Continuous glucose monitoring (CGM) was used to measure the mean amplitude of glycemic excursion (MAGE) and postprandial time in range (TIR) before and after DPP-4 inhibitor treatment to compare glycemic variability.The decrease from baseline in MAGE at 12 weeks after DPP-4 inhibitor treatment was significantly greater in the anagliptin BID group than in the sitagliptin QD group (p0.05); -30.4 ± 25.6 mg/dL (p0.001) in the anagliptin group versus -9.5 ± 38.0 mg/dL (p=0.215) in the sitagliptin group. The TIR after dinner increased by 33.0 ± 22.0% (p0.001) in the anagliptin group and by 14.6 ± 28.2% (p=0.014) in the sitagliptin group, with a statistically significant difference (p=0.009). No statistically significant differences were observed between the groups in the changes in HbA1c and fasting plasma glucose (FPG).The anagliptin BID regimen for the treatment of type 2 diabetes was superior in blood glucose control after dinner to improve glycemic variability, as indicated by MAGE and TIR but equivalent to the QD regimen in terms of HbA1c and FPG. This article is protected by copyright. All rights reserved.
- Published
- 2023
32. Association between environmental cadmium exposure and increased mortality in the U.S. National Health and Nutrition Examination Survey (1999–2018)
- Author
-
Shinje Moon, Junghoon Lee, Jae Myung Yu, Hoonsung Choi, Sohyeon Choi, Jeongim Park, Kyungho Choi, Ejin Kim, Ho Kim, Min Joo Kim, and Young Joo Park
- Subjects
Epidemiology ,Public Health, Environmental and Occupational Health ,Toxicology ,Pollution - Published
- 2023
33. Efficacy and safety of monotherapy with enavogliflozin in Korean patients with type 2 diabetes mellitus: Results of a 12‐week, multicentre, randomized, double‐blind, placebo‐controlled, phase 2 trial
- Author
-
Ye Seul Yang, Kyung Wan Min, Seok‐O Park, Kyung‐Soo Kim, Jae Myung Yu, Eun‐Gyoung Hong, Sung Rae Cho, Kyu Chang Won, Yong Hyun Kim, Seungjoon Oh, Sung Hee Choi, Gwanpyo Koh, Wan Huh, Su Young Kim, and Kyong Soo Park
- Subjects
Endocrinology ,Endocrinology, Diabetes and Metabolism ,Internal Medicine - Published
- 2023
34. Author response for 'Efficacy and Safety of Monotherapy with Enavogliflozin in Korean Patients with Type 2 Diabetes Mellitus: Results of a 12‐week, multi‐center, randomized, double‐blind, placebo‐controlled, phase 2 trial'
- Author
-
null Ye Seul Yang, null Kyung Wan Min, null Seok‐O Park, null Kyung‐Soo Kim, null Jae Myung Yu, null Eun‐Gyoung Hong, null Sung Rae Cho, null Kyu Chang Won, null Yong Hyun Kim, null Seungjoon Oh, null Sung Hee Choi, null Gwanpyo Koh, null Wan Huh, null Su Young Kim, and null Kyong Soo Park
- Published
- 2023
35. Efficacy and safety of enavogliflozin, a novel <scp>SGLT2</scp> inhibitor, in Korean people with type 2 diabetes: A 24‐week, multicentre, randomized, double‐blind, placebo‐controlled, phase <scp>III</scp> trial
- Author
-
Soo Heon Kwak, Kyung Ah Han, Kyung‐Soo Kim, Jae Myung Yu, EunSook Kim, Jong Chul Won, Jun Goo Kang, Choon Hee Chung, Seungjoon Oh, Sung Hee Choi, Kyu Chang Won, Sin Gon Kim, Seung Ah Cho, Bo Young Cho, and Kyong Soo Park
- Subjects
Endocrinology ,Endocrinology, Diabetes and Metabolism ,Internal Medicine - Published
- 2023
36. Author response for 'Efficacy and safety of enavogliflozin, a novel <scp>SGLT2</scp> inhibitor, in Korean people with type 2 diabetes: a 24‐week, multicentre, randomised, double‐blind, placebo‐controlled, phase <scp>III</scp> trial'
- Author
-
null Soo Heon Kwak, null Kyung Ah Han, null Kyung‐Soo Kim, null Jae Myung Yu, null EunSook Kim, null Jong Chul Won, null Jun Goo Kang, null Choon Hee Chung, null Seungjoon Oh, null Sung Hee Choi, null Kyu Chang Won, null Sin Gon Kim, null Seung Ah Cho, null Bo Young Cho, and null Kyong Soo Park
- Published
- 2023
37. Framingham Risk Score Assessment in Subjects with Pre-diabetes and Diabetes: A Cross-Sectional Study in Korea
- Author
-
Won Kim, Kee Ho Song, Kyu Jeung Ahn, Tae Sun Park, Kyoung Hwa Lee, Jae Myung Yu, Seung Hyun Ko, Ho Sang Shon, Sung Hee Choi, Hyuk-Sang Kwon, Dong Sun Kim, and Il Seong Nam-Goong
- Subjects
medicine.medical_specialty ,Framingham Risk Score ,Cross-sectional study ,business.industry ,Endocrinology, Diabetes and Metabolism ,risk assessment ,medicine.disease ,Left ventricular hypertrophy ,RC648-665 ,Diseases of the endocrine glands. Clinical endocrinology ,cardiovascular diseases ,chemistry.chemical_compound ,Blood pressure ,chemistry ,Internal medicine ,Diabetes mellitus ,diabetes mellitus ,Clinical endpoint ,Medicine ,Original Article ,Glycated hemoglobin ,Risk assessment ,business - Abstract
Background : This study aimed to evaluate cardiovascular risk in subjects with pre-diabetes and diabetes in Korea. Methods : In this pan-Korean, non-interventional, cross-sectional study, data were collected from medical records of 10 hospitals between November 2013 and June 2014. Subjects (aged ≥40 years) with medical records of dysglycemia and documentation of total cholesterol level, high-density lipoprotein cholesterol level, systolic blood pressure, and smoking status in the past 6 months were included. The primary endpoint was to determine the Framingham risk score (FRS). The relationships between FRS and cardiovascular risk factors, glycated hemoglobin, and insulin usage were determined by multiple linear regression analyses. Results : Data from 1,537 subjects with pre-diabetes (n=1,025) and diabetes (n=512) were analyzed. The mean FRS (mean±standard deviation) in subjects with pre-diabetes/diabetes was 13.72±8.77. FRS was higher in subjects with diabetes than pre-diabetes (P
- Published
- 2021
38. Efficacy and Safety of Switching to Teneligliptin in Patients with Type 2 Diabetes Inadequately Controlled with Dipeptidyl Peptidase-4 Inhibitors: 52-Week Results from a Prospective Observational Study
- Author
-
Young Sik Kim, Tae Ho Kim, Eun Jung Kyung, Kwan Woo Lee, Yeo Kyeong Kim, Soo Kyoung Kim, Jae Myung Yu, Hae Jin Kim, Kyu Jeung Ahn, Ji Hyun Lee, Chang Beom Lee, Moon Gi Choi, Kyung Wan Min, and Hyuk Jae Chang
- Subjects
medicine.medical_specialty ,endocrine system diseases ,business.industry ,Endocrinology, Diabetes and Metabolism ,nutritional and metabolic diseases ,Diabetes mellitus, type 2 ,Type 2 diabetes ,Teneligliptin ,medicine.disease ,Gastroenterology ,Internal medicine ,Diabetes mellitus ,Internal Medicine ,Clinical endpoint ,Medicine ,Population study ,business ,Adverse effect ,Dipeptidyl peptidase-4 ,medicine.drug ,Glycemic ,Original Research ,Dipeptidyl peptidase IV inhibitors - Abstract
Introduction The aim of this study was to assess the efficacy and safety of switching to teneligliptin from other dipeptidyl peptidase-4 (DPP-4) inhibitors in patients with type 2 diabetes mellitus (T2DM) inadequately controlled despite treatment with a stable dose of other DPP-4 inhibitors. Methods Patients with glycosylated hemoglobin (HbA1c) ≥ 7% despite taking DPP-4 inhibitors other than teneligliptin, with or without other antidiabetic agents, for at least 3 months were enrolled in this study. Patients on DPP-4 inhibitors administered prior to participation in this study were switched to 20 mg teneligliptin once daily and the dose was maintained for the 52-week study period. The primary endpoint was the change in HbA1c at week 12. Fasting plasma glucose (FPG) and the blood lipid profile were also evaluated. Adverse events were monitored for safety assessment. Results At weeks 12, 24, and 52, the HbA1c values significantly decreased by − 0.39, − 0.44, and − 0.52%, respectively, compared to the baseline value (p
- Published
- 2021
39. Author response for 'Anagliptin twice‐daily regimen improves glycemic variability in subjects with type 2 diabetes: <scp>Double‐Blind</scp> , Randomized Controlled Trial'
- Author
-
null Yong‐ho Lee, null Doo‐Man Kim, null Jae Myung Yu, null Kyung Mook Choi, null Sin Gon Kim, null Kang Seo Park, null Hyun‐Shik Son, null Choon Hee Chung, null Kyu Jeung Ahn, null Soon Hee Lee, null Ki‐Ho Song, null Su Kyoung Kwon, null Hyeong Kyu Park, null Kyu Chang Won, null Hak Chul Jang, and null the ACACIA Study Group
- Published
- 2022
40. Implication of diet and exercise on the management of age-related sarcopenic obesity in Asians
- Author
-
Yoon Jung Kim, Shinje Moon, Jae Myung Yu, and Hye Soo Chung
- Subjects
Sarcopenia ,Asian People ,Body Composition ,Humans ,General Medicine ,Obesity ,Muscle, Skeletal ,Exercise ,Aged ,Diet - Abstract
The incidence of sarcopenic obesity among adults aged ≥65 years is rising worldwide. Sarcopenic obesity is a high-risk geriatric syndrome defined as a gain in the amount of adipose tissue along with the age-related loss of muscle mass and strength or physical performance. Sarcopenic obesity is associated with increased risks of falls, physical limitations, cardiovascular diseases, metabolic diseases, and/or mortality. Thus, the identification of preventive and treatment strategies against sarcopenic obesity is important for healthy aging. Diet and exercise are the reasons for the development of sarcopenic obesity and are key targets in its prevention and treatment. Regarding weight reduction alone, it is most effective to maintain a negative energy balance with dietary calorie restriction and aerobic exercise. However, it is important to preserve skeletal muscle mass while reducing fat mass. Resistance exercise and appropriate protein supply are the main ways of preserving skeletal muscle mass, as well as muscle function. Therefore, in order to improve sarcopenic obesity, a complex treatment strategy is needed to limit energy ingestion with proper nutrition and to increase multimodal exercises. In this review, we focus on recently updated interventions for diet and exercise and potential future management strategies for Asian individuals with aging-related sarcopenic obesity. Geriatr Gerontol Int 2022; 22: 695-704.
- Published
- 2022
41. Efficacy and Safety of the Controlled-release Pregabalin Tablet (GLA5PR GLARS-NF1) and Immediate-release Pregabalin Capsule for Peripheral Neuropathic Pain: A Multicenter, Randomized, Double-blind, Parallel-group, Active-controlled, Phase III Clinical Trial
- Author
-
Jae Myung Yu, Jeong Hun Suh, Youngkwon Ko, Sang Sik Choi, KyungWan Min, Min Kyung Lee, Jae Hyuk Lee, Sun Ok Song, Younghoon Jeon, Yong Chul Kim, Sung Eun Sim, and Pyung Bok Lee
- Subjects
Male ,Pregabalin ,02 engineering and technology ,030204 cardiovascular system & hematology ,Hospital Anxiety and Depression Scale ,03 medical and health sciences ,020210 optoelectronics & photonics ,0302 clinical medicine ,Double-Blind Method ,0202 electrical engineering, electronic engineering, information engineering ,medicine ,Humans ,Single-Blind Method ,Pharmacology (medical) ,Adverse effect ,Depression (differential diagnoses) ,Aged ,Pharmacology ,Analgesics ,business.industry ,Middle Aged ,Clinical trial ,Regimen ,Treatment Outcome ,Tolerability ,Delayed-Action Preparations ,Anesthesia ,Neuralgia ,Anxiety ,Female ,medicine.symptom ,business ,Tablets ,medicine.drug - Abstract
Purpose This study compared the efficacy and safety of controlled-release pregabalin (GLA5PR GLARS-NF1 tablets) with those of an immediate-release pregabalin capsule after 12 weeks' administration to patients with peripheral neuropathic pain. Methods In this multicenter, randomized, double-blind, active-controlled, parallel-group, Phase III study, the primary outcome was to confirm that a single treatment with the study drug (after the evening meal) is clinically noninferior to the control drug (BID regimen) at improving the mean Daily Pain Rating Scale score for treating peripheral neuropathic pain. Secondary outcomes were the Daily Sleep Interference Scale, Medical Outcomes Study Sleep Scale, Hospital Anxiety and Depression scale, and frequency of rescue medication use. The safety and tolerability of GLA5PR GLARS-NF1 tablets were also evaluated. The total daily dose of pregabalin is 150–600 mg. Findings Of the 352 randomized subjects, 261 (n = 130, study group; n = 131, control group) were analyzed. The difference in adjusted mean Daily Pain Rating Scale scores between the groups was −0.11 (95% confidence interval, −0.05 to 0.30), indicating that the study group is noninferior to the control group. There was no statistically significant difference in Daily Sleep Interference Scale, Medical Outcomes Study Sleep Scale, and Hospital Anxiety and Depression scale scores between the groups at treatment termination. Logistic regression analysis revealed no significant difference in the use of rescue medication between the groups (P = 0.217). The overall adverse event profile of the groups was similar, and no serious adverse drug reactions were observed. Implications GLA5PR GLARS-NF1 tablets can be effectively and safely administered to patients with peripheral neuropathic pain. Furthermore, we found that sleep, anxiety, and depression were improved with pain control. Owing to the once-daily administration, treatment effects can be maximized by improved treatment compliance. ClinicalTrials.gov identifier: NCT03221907.
- Published
- 2020
42. A Prospective Randomized, Double-Blind, Multi-Center, Phase III Clinical Trial Evaluating the Efficacy and Safety of Olmesartan/Amlodipine plus Rosuvastatin Combination Treatment in Patients with Concomitant Hypertension and Dyslipidemia: A LEISURE Study
- Author
-
Sang-Ho Jo, Seok Min Kang, Byung Su Yoo, Young Soo Lee, Ho Joong Youn, Kyungwan Min, Jae Myung Yu, Hyun Ju Yoon, Woo Shik Kim, Gee Hee Kim, Jae Hyoung Park, Seok Yeon Kim, and Cheol Ho Kim
- Subjects
single pill combination ,phase III clinical trial ,Medicine ,olmesartan ,amlodipine ,rosuvastatin ,General Medicine ,Article - Abstract
Background: This study was a multicenter, randomized, double-blinded, placebo-controlled phase III clinical trial to investigate the efficacy and safety of an olmesartan/amlodipine single pill plus rosuvastatin combination treatment for patients with concomitant hypertension and dyslipidemia. Methods: Patients with both hypertension and dyslipidemia aged 20–80 were enrolled from 36 tertiary hospitals in Korea from January 2017 to April 2018. Patients were randomized to three groups in a 1:1:0.5 ratio, olmesartan/amlodipine single pill plus rosuvastatin (olme/amlo/rosu) or olmesartan plus rosuvastatin (olme/rosu) or olmesartan/amlodipine single pill (olme/amlo) combination. The primary endpoints were change of sitting systolic blood pressure (sitSBP) from baseline in the olme/amlo/rosu vs. olme/rosu groups and the percentage change of low-density lipoprotein cholesterol (LDL-C) from baseline in the olme/amlo/rosu vs. olme/amlo groups after 8 weeks of treatment. Results: A total of 265 patients were randomized, 106 to olme/amlo/rosu, 106 to olme/rosu and 53 to olme/amlo groups. Baseline characteristics among the three groups did not differ. The mean sitSBP change was significantly larger in the olme/amlo/rosu group with −24.30 ± 12.62 mmHg (from 153.58 ± 10.90 to 129.28 ± 13.58) as compared to the olme/rosu group, −9.72 ± 16.27 mmHg (from 153.71 ± 11.10 to 144.00 ± 18.44 mmHg). The difference in change of sitSBP between the two groups was −14.62± 1.98 mmHg with significance (95% CI −18.51 to −10.73, p < 0.0001). The mean LDL-C reduced significantly in the olme/amlo/rosu group, −52.31 ± 16.63% (from 154.52 ± 30.84 to 72.72 ± 26.08 mg/dL) as compared to the olme/amlo group with no change, −2.98 ± 16.16% (from 160.42 ± 32.05 to 153.81 ± 31.57 mg/dL). Significant difference in change was found in LDL-C between the two groups with −50.10 ± 2.73% (95% CI −55.49 to −44.71, p < 0.0001). Total adverse drug reaction rates were 10.48%, 5.66% and 3.7% in the olme/amlo/rosu, olme/rosu and olme/amlo groups, respectively with no statistical significance among the three groups. Serious adverse drug reactions did not occur. Conclusions: Olmesartan/amlodipine single pill plus rosuvastatin combination treatment for patients with both hypertension and dyslipidemia is effective and safe as compared to either olmesartan plus rosuvastatin or olmesartan plus amlodipine treatment.
- Published
- 2022
- Full Text
- View/download PDF
43. Association between body shape index and risk of mortality in the United States
- Author
-
Heysoo Lee, Hye Soo Chung, Yoon Jung Kim, Min Kyu Choi, Yong Kyun Roh, Wankyo Chung, Jae Myung Yu, Chang-Myung Oh, and Shinje Moon
- Subjects
Multidisciplinary ,Cardiovascular Diseases ,Somatotypes ,Humans ,Waist Circumference ,Nutrition Surveys ,United States ,Body Mass Index - Abstract
The body mass index (BMI) neither differentiates fat from lean mass nor does it consider adipose tissue distribution. In contrast, the recently introduced z-score of the log-transformed A Body Shape Index (LBSIZ) can be applied to measure obesity using waist circumference (WC), height, and weight. We aimed to investigate the association between LBSIZ and mortality. We used data from the National Health and Nutrition Examination Survey 1999–2014 and linked the primary dataset to death certificate data from the National Death Index with mortality follow-up through December 31, 2015. A multiple Cox regression analysis was performed to evaluate the hazard ratio (HR) of all-cause and cardiovascular disease (CVD) mortalities with adjustment for baseline characteristics. LBSIZ, WC, and BMI showed positive association with total fat percentage (P
- Published
- 2021
44. Nocturia as a Risk Factor for All-Cause and Cardiovascular Disease Mortality
- Author
-
Shinje Moon, Yoon Jung Kim, Hye Soo Chung, Jae Myung Yu, Il In Park, Sung Gon Park, Sahyun Pak, Ohseong Kwon, Young Goo Lee, and Sung Tae Cho
- Subjects
urologic and male genital diseases ,female genital diseases and pregnancy complications - Abstract
This study aimed to evaluate the relationship between nocturia and mortality risk using the National Health and Nutrition Examination Survey database 2005–2010, given that only few studies have investigated nocturia or its association with mortality using this database. Data were obtained from the database, and nocturia was defined based on the symptom questionnaire. We categorized patients into two groups: mild nocturia (2–3 voids/night) and moderate-to severe nocturia (≥4 voids/night). Mortality data were obtained by linking the primary database to death certificate data found in the National Death Index with mortality follow-up up to December 31, 2015. Multiple Cox proportional hazard regression analyses were performed with adjustment for confounding variables at the baseline survey. We included 9,892 adults (4,758 men, 5,134 women) in this study. Nocturia occurred in 3,314 individuals (33.5%). In the multiple Cox regression analysis (results presented as hazard ratio, 95% confidence interval), nocturia was significantly associated with all-cause (1.21, 1.08–1.35, p=0.001) and cardiovascular disease (1.45, 1.13–1.85, p=0.003) mortality. Both mild and moderate-to-severe nocturia were significantly associated with all-cause (1.14, 1.02–1.28, p=0.021 and 1.62, 1.34–1.98, p
- Published
- 2021
45. Real-World Analysis of Rapid-Acting Insulin Analog Use and Its Blood Glucose Lowering Effect in Patients with Type 2 Diabetes Mellitus: Results from PASSION Disease Registry in Korea
- Author
-
Hye Soon Kim, Jae Myung Yu, Hak Chul Jang, Eui Kwang Choi, Jeong Hyun Park, Ho Sang Shon, Choon Hee Chung, Keun-Gyu Park, Jae Hyoung Cho, Won Kim, Kyoung Hwa Lee, Jee Hyun Lee, and Soon Jib Yoo
- Subjects
Pharmacology ,Internal Medicine ,Targets and Therapy [Diabetes, Metabolic Syndrome and Obesity] - Abstract
Hye Soon Kim,1 Jae Myung Yu,2 Hak Chul Jang,3 Eui Kwang Choi,4 Jeong Hyun Park,5 Ho Sang Shon,6 Choon Hee Chung,7 Keun-Gyu Park,8 Jae Hyoung Cho,9 Won Kim,10 Kyoung Hwa Lee,10 Jee Hyun Lee,10 Soon Jib Yoo11 1Department of Internal Medicine, Keimyung University School of Medicine, Daegu, Republic of Korea; 2Department of Internal Medicine, Kangnam Sacred Heart Hospital, Hallym University Medical Center, Hallym University College of Medicine, Seoul, Republic of Korea; 3Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Republic of Korea; 4Department of Internal Medicine, Naedang Dr. Choiâs Clinic, Seoul, Republic of Korea; 5Department of Internal Medicine, College of Medicine, Inje University, Busan, Republic of Korea; 6Department of Internal Medicine, Catholic University of Daegu, School of Medicine, Daegu, Republic of Korea; 7Department of Internal Medicine, Yonsei University Wonju College of Medicine, Wonju, Republic of Korea; 8Department of Internal Medicine, School of Medicine, Kyungpook National University, Kyungpook National University Hospital, Daegu, Republic of Korea; 9Department of Endocrinology and Metabolism, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea; 10Medical Department Sanofi-Aventis Korea, Seoul, Republic of Korea; 11Department of Internal Medicine, Bucheon St. Maryâs Hospital, College of Medicine, The Catholic University of Korea, Bucheon, Republic of KoreaCorrespondence: Soon Jib Yoo, Department of Internal Medicine, Bucheon St. Maryâs Hospital, College of Medicine, The Catholic University of Korea, Bucheon, 14647, Republic of Korea, Tel +82-32-340-7011, Fax +82-32-340-2039, Email sjyoomt@gmail.comPurpose: Although rapid-acting insulins (RAIs) are used frequently in Korean clinical settings, evidence on their use is limited. This study explores the pattern and clinical effectiveness of the use of RAIs in Korean patients with type 2 diabetes mellitus (T2DM).Patients and Methods: This non-interventional, observational study enrolled patients (aged > 18 years) with T2DM who were prescribed RAIs. The pattern of use and effectiveness of RAI analogs were evaluated over 6 months.Results: A total of 299/451 patients were analyzed. Approximately 90% (n/N=270/299) of the patients received insulin glulisine, which significantly reduced their levels of glycated hemoglobin (HbA1c: n=270, mean± standard deviation [SD]; â 1.16± 6.02%, p=0.0017), fasting plasma glucose (n=40; mean±SD: â 54.9± 90.89 mg/dl, p=0.0005), and post prandial blood glucose (n=35, mean±SD: â 89.46± 105.68 mg/dl, p< 0.0001) at 6 months, with a corresponding increase in body weight (BW) (n=197, mean±SD:1.45± 3.64 kg, p< 0.0001). At 6 months, more patients receiving an intensive regimen (basal insulin+⥠2 RAI injections/day) had HbA1c < 7% than those receiving a non-intensive regimen (basal insulin+1 RAI injection/day) (20.69% vs 7.46%; p=0.0333); the corresponding reduction in HbA1c was also higher in patients receiving the intensive regimen (p< 0.0001). About one-fourth patients (n/N=22/95) were switched to the intensive regimen (from 1 to ⥠2 RAI injections/day), and only 4.41% (n/N=9/204) of the patients were switched to 1 RAI injection/day. The patients receiving the intensive regimen showed higher levels of HbA1c reductions (mean±SD: â 1.27± 1.96%) compared with the maintenance group-1 RAI injection/day (mean±SD: â 0.72± 1.66%) (p=0.0459), without a significant increase in BW and body mass index.Conclusion: The insulin glulisine intensification regimen showed glycemic target achievement and can be considered a therapeutic tool in the management of T2DM patients.Keywords: glycated hemoglobin, insulin glulisine, intensification, RAI analogs
- Published
- 2021
46. Efficacy and Safety of the New Appetite Suppressant, Liraglutide: A Meta-Analysis of Randomized Controlled Trials
- Author
-
Yoon Jung Kim, Jae Myung Yu, Sung Hoon Yu, Jibeom Lee, Chang-Myung Oh, Hye Soo Chung, and Shinje Moon
- Subjects
obesity ,medicine.medical_specialty ,Endocrinology, Diabetes and Metabolism ,Overweight ,Gastroenterology ,metabolic syndrome ,Diseases of the endocrine glands. Clinical endocrinology ,law.invention ,chemistry.chemical_compound ,Endocrinology ,Randomized controlled trial ,law ,Diabetes mellitus ,Internal medicine ,Appetite Depressants ,Weight Loss ,medicine ,Humans ,Diabetes, Obesity and Metabolism ,Randomized Controlled Trials as Topic ,Glycated Hemoglobin ,liraglutide ,Liraglutide ,business.industry ,RC648-665 ,medicine.disease ,United States ,glucagon-like peptide 1 ,meta-analysis ,Blood pressure ,chemistry ,Original Article ,Glycated hemoglobin ,Metabolic syndrome ,medicine.symptom ,business ,Body mass index ,medicine.drug - Abstract
Background Obesity is a chronic disease associated with metabolic diseases such as diabetes and cardiovascular disease. Since the U.S. Food and Drug Administration approved liraglutide as an anti-obesity drug for nondiabetic patients in 2014, it has been widely used for weight control in overweight and obese people. This study aimed to systematically analyze the effects of liraglutide on body weight and other cardiometabolic parameters. Methods We investigated articles from PubMed, EMBASE, and the Cochrane Library to search randomized clinical trials that examined body weight changes with liraglutide treatment. Results We included 31 studies with 8,060 participants for this meta-analysis. The mean difference (MD) between the liraglutide group and the placebo group was -4.19 kg (95% confidence interval [CI], -4.84 to -3.55), with a -4.16% change from the baseline (95% CI, -4.90 to -3.43). Liraglutide treatment correlated with a significantly reduced body mass index (MD: -1.55; 95% CI, -1.76 to -1.34) and waist circumference (MD: -3.11 cm; 95% CI, -3.59 to -2.62) and significantly decreased blood pressure (systolic blood pressure, MD: -2.85 mm Hg; 95% CI, -3.36 to -2.35; diastolic blood pressure, MD: -0.66 mm Hg; 95% CI, -1.02 to -0.30), glycated hemoglobin (MD: -0.40%; 95% CI, -0.49 to -0.31), and low-density lipoprotein cholesterol (MD: -2.91 mg/dL; 95% CI, -5.28 to -0.53; MD: -0.87% change from baseline; 95% CI, -1.17 to -0.56). Conclusion Liraglutide is effective for weight control and can be a promising drug for cardiovascular protection in overweight and obese people.
- Published
- 2021
47. Efficacy and Safety of Omega-3 Fatty Acids in Patients Treated with Statins for Residual Hypertriglyceridemia: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial
- Author
-
In Kyung Jeong, Dong-Bin Kim, Mi-Seung Shin, Sang Ah Lee, Seung Ho Kang, Kyung Mook Choi, Moon Kyu Lee, Yong Ho Lee, Sung Hee Choi, Ji Eun Jun, Jae Hyuk Lee, Seok Yeon Kim, Jin Man Cho, Jae Myung Yu, Sung Rae Kim, Ho-Cheol Kang, Hyeong Kyu Park, Kyung Ah Han, Won-Yong Shin, Hyuk-Sang Kwon, Sung Ho Her, Ji Oh Mok, In Kye Lee, Kyung Heon Won, So Hun Kim, Soo Kyung Kim, Chang Beom Lee, Sang Ho Jo, Tae Joon Cha, and Hyo Suk Ahn
- Subjects
Male ,medicine.medical_specialty ,Drug/Regimen ,Endocrinology, Diabetes and Metabolism ,Atorvastatin ,030209 endocrinology & metabolism ,030204 cardiovascular system & hematology ,Placebo ,Gastroenterology ,lcsh:Diseases of the endocrine glands. Clinical endocrinology ,03 medical and health sciences ,chemistry.chemical_compound ,0302 clinical medicine ,Double-Blind Method ,Diabetes mellitus ,Internal medicine ,Fatty Acids, Omega-3 ,medicine ,Humans ,Triglycerides ,Aged ,Hypertriglyceridemia ,lcsh:RC648-665 ,Triglyceride ,business.industry ,Cholesterol, HDL ,nutritional and metabolic diseases ,Cholesterol, LDL ,Middle Aged ,medicine.disease ,Eicosapentaenoic acid ,chemistry ,Tolerability ,Linear Models ,lipids (amino acids, peptides, and proteins) ,Original Article ,Female ,Hydroxymethylglutaryl-CoA Reductase Inhibitors ,business ,Dyslipidemia ,medicine.drug - Abstract
Background: Cardiovascular risk remains increased despite optimal low density lipoprotein cholesterol (LDL-C) level induced by intensive statin therapy. Therefore, recent guidelines recommend non-high density lipoprotein cholesterol (non-HDL-C) as a secondary target for preventing cardiovascular events. The aim of this study was to assess the efficacy and tolerability of omega-3 fatty acids (OM3-FAs) in combination with atorvastatin compared to atorvastatin alone in patients with mixed dyslipidemia. Methods: This randomized, double-blind, placebo-controlled, parallel-group, and phase III multicenter study included adults with fasting triglyceride (TG) levels ≥200 and
- Published
- 2019
48. Efficacy and Safety of Switching to Teneligliptin in Patients with Type 2 Diabetes Inadequately Controlled with Dipeptidyl Peptidase-4 Inhibitors: A 12-Week Interim Report
- Author
-
Kyu Jeung Ahn, Ji Hyun Lee, Young Sik Kim, Soo Kyoung Kim, Kyoung Min Kim, Kwan Woo Lee, Jae Myung Yu, Hae Jin Kim, Chang Beom Lee, Tae Ho Kim, Hyuk Jae Chang, and Moon Gi Choi
- Subjects
Dipeptidyl-peptidase IV inhibitors ,medicine.medical_specialty ,endocrine system diseases ,Endocrinology, Diabetes and Metabolism ,Blood lipids ,030209 endocrinology & metabolism ,Teneligliptin ,Type 2 diabetes ,030204 cardiovascular system & hematology ,Gastroenterology ,03 medical and health sciences ,0302 clinical medicine ,Diabetes mellitus, Type 2 ,Internal medicine ,Diabetes mellitus ,Internal Medicine ,Clinical endpoint ,medicine ,Dipeptidyl peptidase-4 ,Original Research ,Glycemic ,business.industry ,nutritional and metabolic diseases ,Type 2 Diabetes Mellitus ,medicine.disease ,business ,medicine.drug - Abstract
Introduction Teneligliptin, an antidiabetic agent classified as a class III dipeptidyl peptidase-4 (DPP-4) inhibitor, has a unique structural feature that provides strong binding to DPP-4 enzymes. We investigated the efficacy and safety of switching patients with type 2 diabetes mellitus (T2DM) who had inadequate glycemic control on a stable dose of other DPP-4 inhibitors to teneligliptin. Methods Patients with T2DM whose glycosylated hemoglobin (HbA1c) levels were ≥ 7% despite taking DPP-4 inhibitors other than teneligliptin, with or without other hypoglycemic agents, for at least 3 months were enrolled. The DPP-4 inhibitors taken before participating in the study were switched to 20 mg qd teneligliptin, and this was to be maintained for 52 weeks. The primary end point was the change in HbA1c levels after 12 weeks. Metabolic parameters including fasting plasma glucose (FPG) and blood lipids were assessed also. To assess safety, adverse and hypoglycemic events were monitored. The data from baseline to week 12 were used for analysis in this interim report. Results The mean change in HbA1c levels from baseline to week 12 was − 0.44%. At week 12, the percentage of patients achieving HbA1c
- Published
- 2019
49. Association between Serum Selenium Level and the Presence of Diabetes Mellitus: A Meta-Analysis of Observational Studies
- Author
-
Jung Hwan Park, Dong Sun Kim, Ju-No Kim, Hyung Joon Yoo, Min-Kyu Choi, Yong Kyun Roh, Jae Myung Yu, Hye Soo Chung, and Shinje Moon
- Subjects
Adult ,Male ,medicine.medical_specialty ,Databases, Factual ,Endocrinology, Diabetes and Metabolism ,030209 endocrinology & metabolism ,Clinical Diabetes & Therapeutics ,Urine ,030204 cardiovascular system & hematology ,Gastroenterology ,lcsh:Diseases of the endocrine glands. Clinical endocrinology ,Antioxidants ,law.invention ,03 medical and health sciences ,Selenium ,0302 clinical medicine ,Diabetes mellitus ,Randomized controlled trial ,law ,Internal medicine ,Epidemiology ,medicine ,Odds Ratio ,Humans ,Aged ,Trace elements ,lcsh:RC648-665 ,business.industry ,Publication bias ,Odds ratio ,Middle Aged ,medicine.disease ,Confidence interval ,Observational Studies as Topic ,Nails ,Meta-analysis ,Original Article ,Female ,business ,Publication Bias - Abstract
Background Epidemiological studies have suggested an association between selenium (Se) and diabetes mellitus (DM). However, different studies have reported conflicting results. Therefore, we performed a comprehensive meta-analysis to clarify the impact of Se on DM. Methods We searched the PubMed database for studies on the association between Se and DM from inception to June 2018. Results Twenty articles evaluating 47,930 participants were included in the analysis. The meta-analysis found that high levels of Se were significantly associated with the presence of DM (pooled odds ratios [ORs], 1.88; 95% confidence interval [CI], 1.44 to 2.45). However, significant heterogeneity was found (I²=82%). Subgroup analyses were performed based on the Se measurement methods used in each study. A significant association was found between high Se levels and the presence of DM in the studies that used blood (OR, 2.17; 95% CI, 1.60 to 2.93; I²=77%), diet (OR, 1.61; 95% CI, 1.10 to 2.36; I²=0%), and urine (OR, 1.49; 95% CI, 1.02 to 2.17; I²=0%) as samples to estimate Se levels, but not in studies on nails (OR, 1.24; 95% CI, 0.52 to 2.98; I²=91%). Because of significant heterogeneity in the studies with blood, we conducted a sensitivity analysis and tested the publication bias. The results were consistent after adjustment based on the sensitivity analysis as well as the trim and fill analysis for publication bias. Conclusion This meta-analysis demonstrates that high levels of Se are associated with the presence of DM. Further prospective and randomized controlled trials are warranted to elucidate the link better.
- Published
- 2019
50. Efficacy and Safety of Voglibose Plus Metformin in Patients with Type 2 Diabetes Mellitus: A Randomized Controlled Trial
- Author
-
In Joo Kim, Moon Kyu Lee, Inkyu Lee, Yong Seong Kim, Hyun Shik Son, Tae Sun Park, Bong Soo Cha, Kun Ho Yoon, Kwan Woo Lee, Sung Woo Park, Tae Jung Oh, In Kyung Jeong, Sung Hee Choi, Jeong Hyung Park, Kyung Wan Min, Young Duk Song, Sung Rae Kim, Jae Myung Yu, Sei Hyun Baik, Doo Man Kim, and Joong Yeol Park
- Subjects
medicine.medical_specialty ,endocrine system diseases ,Endocrinology, Diabetes and Metabolism ,030209 endocrinology & metabolism ,Clinical Diabetes & Therapeutics ,030204 cardiovascular system & hematology ,Hypoglycemia ,Gastroenterology ,lcsh:Diseases of the endocrine glands. Clinical endocrinology ,03 medical and health sciences ,0302 clinical medicine ,Weight loss ,Diabetes mellitus ,Internal medicine ,Voglibose ,medicine ,Glycemic ,lcsh:RC648-665 ,business.industry ,Type 2 Diabetes Mellitus ,nutritional and metabolic diseases ,Diabetes mellitus, type 2 ,medicine.disease ,Metformin ,Postprandial ,Original Article ,medicine.symptom ,business ,medicine.drug - Abstract
Background: Combination of metformin to reduce the fasting plasma glucose level and an α-glucosidase inhibitor to decrease the postprandial glucose level is expected to generate a complementary effect. We compared the efficacy and safety of a fixed-dose combination of voglibose plus metformin (vogmet) with metformin monotherapy in drug-naive newly-diagnosed type 2 diabetes mellitus. Methods: A total of 187 eligible patients aged 20 to 70 years, with a glycosylated hemoglobin (HbA1c) level of 7.0% to 11.0%, were randomized into either vogmet or metformin treatments for 24 weeks. A change in the HbA1c level from baseline was mea sured at week 24. Results: The reduction in the levels of HbA1c was -1.62%±0.07% in the vogmet group and -1.31%±0.07% in the metformin group (P=0.003), and significantly more vogmet-treated patients achieved the target HbA1c levels of
- Published
- 2018
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.